Supported Releases: These releases have been certified by Bloomberg’s Enterprise Products team for use by Bloomberg customers. Experimental Releases: These releases have not yet been certified for use ...
Novartis' programme providing free access to its spinal muscular atrophy (SMA) gene therapy Zolgensma is being scaled back to a dozen countries worldwide, according to the company. First introduced in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results